Fondazione Don Gnocchi
Sant'Angelo dei Lombardi, Avellino, 83054, Italy
NCT Number: NCT06920511
The OPERA Clinical Study is an interventional, single-arm, open-label pilot clinical study that aims to evaluate the usability of an innovative bio-cooperative robotic platform (PRoBio) for cognitive rehabilitation in patients with Parkinson's Disease (PD) and Mild Cognitive Impairment (MCI). The study focuses on assessing the effectiveness and acceptability of the system in a pilot study involving patients undergoing a structured cognitive rehabilitation program.
PRoBio is an advanced rehabilitation platform that integrates the TIAGo robotic system, developed by PAL Robotics, with the VRRS COMPACT virtual reality rehabilitation system, designed by Khymeia. TIAGo is provided by a robotic arm and RGB-D camera that allow the collection of biomechanical and psychophysiological data, which are then used to personalize the treatment through the cognitive tasks provided by the VRRS COMPACT. The pilot study involves patients with PD-MCI, who will undergo a four-week rehabilitation program with ProBio, consisting of three weekly sessions of virtual cognitive training. The primary objective is to assess the usability and compliance of the system by evaluating user experience, ease of interaction, and engagement levels among both patients and rehabilitation professionals, as well as evaluating its ability to monitor biomechanical and psychophysiological parameters during treatment. This assessment will be conducted using a multimodal sensor system, which includes an RGB-D camera integrated into the UCBM TIAGo robot and wearable sensors designed to measure heart rate, respiratory rate, and galvanic skin response. The data collected through these sensors will be analyzed offline to personalize cognitive rehabilitation treatments in subsequent sessions. Additionally, the study aims to evaluate the accuracy and response times of patients while performing cognitive exercises, as recorded by the VRRS system. Furthermore, the study will explore the potential effects of PRoBio treatment on the cognitive functions of patients with Parkinson's Disease and Mild Cognitive Impairment (PD-MCI) as a possible future rehabilitation to include in the clinical practice.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Sant'Angelo dei Lombardi, Avellino, 83054, Italy
The pilot study will be conducted at two clinical centers, the Fondazione Don Carlo Gnocchi ONLUS sites in Sant'Angelo dei Lombardi (AV) and Florence (FI).
The first step involves obtaining informed consent from all participants. Following this, a baseline assessment (T0) will be carried out, including the collection of demographic and anamnesis data, as well as cognitive and psychological evaluations. These assessments will help confirm eligibility criteria and serve as a pre-treatment evaluation for enrolled patients. The assessment tools include the MDS-Unified Parkinson's Disease Rating Scale, the Parkinson's Disease Cognitive Rating Scale, the Stroop Color Word Test, the Trail Making Test (A and B), the Parkinson's Disease Questionnaire (PDQ-39), the 15-item Geriatric Depression Scale, and the Geriatric Anxiety Inventory.
Once baseline evaluations are completed, patients will begin a structured cognitive rehabilitation program using the ProBio platform, which integrates the UCBM TIAGo service robot with the VRRS COMPACT telerehabilitation system developed by Khymeia. The rehabilitation program will consist of three weekly sessions, each lasting 45 minutes, for a total duration of four weeks. The cognitive tasks and activities will be tailored to the individual patient's abilities to provide a personalized treatment plan aimed at improving specific cognitive functions. During the rehabilitation sessions, UCBM TIAGo will continuously monitor the patient's physical and emotional state, collecting data through advanced sensors and its integrated RGB-D camera. These data will be analyzed offline to adjust the complexity and intensity of exercises for subsequent sessions based on individual responses.
Throughout the treatment, several parameters will be recorded. The accuracy and response times in cognitive exercises will be documented in reports generated by the VRRS software. Biomechanical parameters, such as movement amplitude and speed, will be measured using the RGB-D camera, while psychophysiological parameters, including respiratory rate, heart rate, and skin conductance, will be monitored via wearable sensors. Based on these parameters, the VRRS system will provide real-time visual and vocal feedback to the patient regarding response accuracy and exercise execution. Additionally, at the end of each session, the bio-cooperative robot TIAGo will verbally interact with the patient to assess their experience, including perceived enjoyment, task comprehension, and ease of execution.
At the end of the four-week rehabilitation program, a final evaluation (T1) will be conducted using the same cognitive and psychological assessment tools applied at baseline. This will include the MDS-Unified Parkinson's Disease Rating Scale, the Parkinson's Disease Cognitive Rating Scale, the Stroop Color Word Test, the Trail Making Test, the Parkinson's Disease Questionnaire (PDQ-39), the 15-item Geriatric Depression Scale, and the Geriatric Anxiety Inventory. The study also aims to explore the potential of integrating robotic bio-cooperative platforms into routine clinical rehabilitation settings, providing insights into their feasibility and effectiveness for future large-scale applications.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention consists of a cognitive rehabilitation program using the PRoBio platform, a bio-cooperative robotic system integrating virtual reality and real-time multisensory feedback. The PRoBio platform includes a robotic arm (TIAGo), a virtual reality interface (VRRS), and sensors to monitor biomechanical, cognitive, and emotional parameters during training.
Other names: TIAGo, COMPACT VRRS, Robotic Bio-Cooperative Training, Virtual Reality Rehabilitation with PRoBio, PRoBio platform
Time frame: Week 4 (post-treatment, T1)
Assessment of system usability using the 10-item SUS scale. Scores range from 0 to 100; higher scores indicate better usability.
Time frame: Week 4 (post-treatment, T1)
Assessment of system usability using the HUBBI questionnaire. Items rated on a 7-point scale; higher scores indicate better usability.
Time frame: Week 4 (post-treatment, T1)
Evaluation of pragmatic and hedonic user experience with the UEQ-S. Each item rated from -3 to +3; higher scores indicate more positive experience.
Time frame: Week 4 (post-treatment, T1)
Evaluation of perceived usefulness and ease of use via TAM and UTAUT scales. Items rated on 5-point Likert scales.
Time frame: Week 4 (post-treatment, T1)
Evaluation of cognitive workload using the NASA-TLX scale. Scores range from 0 to 100; higher scores indicate higher workload.
Time frame: Weeks 1-4
Evaluation of the acceptance of the PRoBio platform by patients and clinicians, based on session attendance, treatment adherence, and system usability for operators. Additionally, the ability of PRoBio to collect biomechanical and psychophysiological data during treatment will be assessed. These include response accuracy and reaction times (collected by VRRS), movement amplitude and velocity (via RGB-D camera), and physiological indicators (heart rate, respiratory rate, and skin conductance) recorded through wearable sensors. These data will be used offline to customize the rehabilitation sessions.
Time frame: Weeks 1-4
Accuracy rate in exercises performed during each session, as recorded by VRRS.
Time frame: Weeks 1-4
Mean reaction times (ms) recorded during cognitive tasks using the PRoBio platform.
Time frame: Weeks 1-4
Mean amplitude of upper limb movements captured via RGB-D camera.
Time frame: Weeks 1-4
Mean velocity of arm movements during tasks, as measured by RGB-D camera.
Time frame: Weeks 1-4
Average heart rate recorded during rehabilitation sessions.
Time frame: Weeks 1-4
Average respiratory rate recorded during sessions.
Time frame: Weeks 1-4
Average SCL value measured by wearable sensors as indicator of emotional arousal.
Time frame: Baseline (T0) and Week 4 (T1)
PD-CRS scores will be collected to evaluate changes in cognitive performance. Scores range from 0 to 134; higher scores indicate better cognition.
Time frame: Baseline (T0) and Week 4 (T1)
Performance on SCWT will be measured by response times and error rate.
Time frame: Baseline (T0) and Week 4 (T1)
Completion time (in seconds) for TMT-A and TMT-B will be recorded.
Time frame: Baseline (T0) and Week 4 (T1)
Quality of life will be measured through the PDQ-39. Scores range from 0 to 100; lower scores indicate better quality of life.
Time frame: Baseline (T0) and Week 4 (T1)
Scores range from 0 to 15; higher scores indicate more depressive symptoms.
Time frame: Baseline (T0) and Week 4 (T1)
Scores range from 0 to 20; higher scores indicate greater anxiety.
Contact information is provided by the study sponsor or research team.
Fondazione Don Carlo Gnocchi ETS
Other
Integrated biO-cooPErative Robotic plAtform for Virtual Cognitive-motor Training in Parkinson's Disease
Acronym: OPERA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07523425
Basal Ganglia Diseases, Brain Diseases
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT07701668
Behavior, Cognition Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT07703267
Cognition Disorders, Cognitive Dysfunction
View Trial DetailsNCT07656389
Central Nervous System Diseases, Cognition Disorders
Tainan, Taiwan
View Trial Details